Millennium Over-Delivers on 2007 Goals and Financia...(- In 2007 VELCADE strengthened its posi...)

treatment for relapsed multiple myeloma and mantle cell lymphoma.

Sales increased steadily throughout the year as a result of the

increasing impact of the Company's enhanced sales and marketing

programs, which improved share-of-voice for the product in the market.

-- The Company submitted a supplemental New Drug Application (sNDA) to

the U.S. Food and Drug Administration (FDA) in December 2007 for

VELCADE expansion into newly diagnosed multiple myeloma. The filing,

based on data from the Phase III VISTA trial, conducted with its

co-development partner, Johnson & Johnson Pharmaceutical Research &

Development, L.L.C. (J&JPRD), was granted priority review by the FDA.

The FDA decision date for the sNDA is scheduled for June 20, 2008.

J&JPRD submitted a corresponding marketing application to the European

Medicines Evaluation Agency (EMEA).

-- Data from three large, well-controlled Phase III clinical trials of

VELCADE based combinations in newly diagnosed multiple myeloma were

featured at the 2007 Annual Meeting of the American Society of

Hematology (ASH). These trials are part of a comprehensive development

program designed to establish VELCADE as a critical component of the

standard of care regimens in the multiple myeloma transplant and

non-transplant settings. Data from the three Phase III trials are as

follows:

-- VISTA -- The combination therapy of VELCADE, melphalan and

prednisone (VcMP) showed statistically significant improvement

across all efficacy endpoints when compared to melphalan and

prednisone (MP) alone in 682 patients ineligible for stem cell

transplantation (SCT). Patients treated with VcMP had a 35 percent

'/>"/>